Can Fite Biopharma Ltd ADR (CANF) - Total Liabilities
Based on the latest financial reports, Can Fite Biopharma Ltd ADR (CANF) has total liabilities worth $3.92 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CANF shareholders equity momentum to track the company's year-over-year net asset growth rate.
Can Fite Biopharma Ltd ADR - Total Liabilities Trend (2011–2025)
This chart illustrates how Can Fite Biopharma Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. See CANF cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Can Fite Biopharma Ltd ADR Competitors by Total Liabilities
The table below lists competitors of Can Fite Biopharma Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Armada Berjaya Trans Tbk PT
JK:JAYA
|
Indonesia | Rp150.47 Billion |
|
Sakol Energy Public Company Limited
BK:SKE
|
Thailand | ฿755.26 Million |
|
Moving iMage Technologies Inc
NYSE MKT:MITQ
|
USA | $4.46 Million |
|
Amaze Holdings Inc
NYSE MKT:AMZE
|
USA | $24.44 Million |
|
The North American Income Trust plc
LSE:NAIT
|
UK | GBX41.74 Million |
|
Dreamland Limited Class A Ordinary Shares
NASDAQ:TDIC
|
USA | $49.81 Million |
|
Stardust Power Inc.
NASDAQ:SDST
|
USA | $15.16 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Can Fite Biopharma Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Can Fite Biopharma Ltd ADR market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Can Fite Biopharma Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Can Fite Biopharma Ltd ADR (2011–2025)
The table below shows the annual total liabilities of Can Fite Biopharma Ltd ADR from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.92 Million | +6.46% |
| 2024-12-31 | $3.68 Million | -1.66% |
| 2023-12-31 | $3.75 Million | -22.14% |
| 2022-12-31 | $4.81 Million | -18.05% |
| 2021-12-31 | $5.87 Million | +70.22% |
| 2020-12-31 | $3.45 Million | -39.83% |
| 2019-12-31 | $5.73 Million | +16.10% |
| 2018-12-31 | $4.94 Million | +3.32% |
| 2017-12-31 | $4.78 Million | -24.07% |
| 2016-12-31 | $6.29 Million | -12.06% |
| 2015-12-31 | $7.16 Million | +114.89% |
| 2014-12-31 | $3.33 Million | +52.99% |
| 2013-12-31 | $2.18 Million | -7.11% |
| 2012-12-31 | $2.34 Million | +45.41% |
| 2011-12-31 | $1.61 Million | -- |
About Can Fite Biopharma Ltd ADR
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more